Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

243.14 +8.25 (+3.51%)

Official Closing Price Updated: 4:10 PM EDT, Jun 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes ↗

June 17, 2025

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

Via Benzinga

Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗

June 16, 2025

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.

Via Stocktwits

AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence ↗

June 16, 2025

The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in combination with Azacitidine compared to Azacitidine and placebo in the treatment...

Via Stocktwits

1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of

June 16, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

How Is The Market Feeling About AbbVie? ↗

June 11, 2025

Via Benzinga

AbbVie Stock Rises After FDA Approves Expanded Treatment Scope For Mavyret, But Retail Needs More To Cheer ↗

June 11, 2025

The approval makes Mavyret the first and only oral eight-week direct-acting antiviral therapy for people with Acute Hepatitis C Virus.

Via Stocktwits

FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection ↗

June 11, 2025

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

Via Benzinga

Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock ↗

June 10, 2025

Via Benzinga

1 S&P 500 Stock with Competitive Advantages and 2 to Steer Clear Of

June 09, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Economy Stocks

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2025

Via The Motley Fool

Topics Intellectual Property

Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks ↗

June 05, 2025

Via The Motley Fool

Topics Economy World Trade

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗

June 04, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

3 Cheap Dividend Growth Stocks to Buy Right Now ↗

June 04, 2025

Via The Motley Fool

Topics Economy

4 Forever Dividend Stocks to Buy ↗

June 03, 2025

These companies provide growing cash flows.

Via The Motley Fool

Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades' ↗

June 02, 2025

Via Benzinga

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly ↗

May 29, 2025

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 27, 2025

Via Benzinga

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event ↗

May 27, 2025

AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.

Via Benzinga

U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result ↗

May 24, 2025

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.

Via The Motley Fool

Topics Government Supply Chain World Trade

Elon Musk Commits to Tesla. Is That a Good Thing? ↗

May 23, 2025

Via The Motley Fool

2 Incredible Dividend Growth Stocks to Buy Now ↗

May 21, 2025

Via The Motley Fool

Topics Government Intellectual Property

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 20, 2025

Via Benzinga

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut. ↗

May 18, 2025

Here are three dividend-paying stocks that warrant closer examination.

Via The Motley Fool

3 Magnificent Stocks That Are Passive Income Machines ↗

May 17, 2025

Via The Motley Fool

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

1 Healthcare Stock to Keep an Eye On and 2 to Ignore

May 16, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Economy Stocks

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 ↗

May 15, 2025

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Via Benzinga

Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets ↗

May 15, 2025

Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.

Via Benzinga

Topics Bonds

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.